Title : A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein.

Pub. Date : 2020 Jan 9

PMID : 31925328






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Using BCR-ABL as a case study, we successfully recaptured the clinically observed mutations that confer resistance imatinib, nilotinib, dasatinib, bosutinib, and ponatinib. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens